AlphaCentric Advisors LLC Boosts Stock Holdings in Valneva SE (NASDAQ:VALN)

AlphaCentric Advisors LLC boosted its position in Valneva SE (NASDAQ:VALN) by 33.7% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 118,000 shares of the company’s stock after buying an additional 29,748 shares during the quarter. AlphaCentric Advisors LLC owned approximately 0.15% of Valneva worth $717,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Wall Street Analyst Weigh In

Separately, HC Wainwright cut their price objective on shares of Valneva from $23.00 to $20.00 and set a “buy” rating for the company in a report on Friday, October 11th.

Valneva Stock Performance

Shares of VALN opened at $5.85 on Tuesday. The stock has a 50-day moving average price of $6.23 and a 200-day moving average price of $7.18. The company has a market cap of $475.31 million, a PE ratio of -11.25 and a beta of 2.17. The company has a current ratio of 2.63, a quick ratio of 2.15 and a debt-to-equity ratio of 0.97. Valneva SE has a 12-month low of $5.40 and a 12-month high of $14.49.

Valneva (NASDAQ:VALN) last posted its quarterly earnings data on Tuesday, August 13th. The company reported ($0.37) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.02. Valneva had a negative net margin of 21.31% and a negative return on equity of 20.01%. The company had revenue of $40.97 million during the quarter, compared to the consensus estimate of $46.83 million.

Valneva Company Profile

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.